Press releases

The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM has completed the sale of its Braunschweig location to AveThera GmbH. Through this acquisition, the Braunschweig location will now be taken over by a young company that plans to use the location's expertise and infrastructure to develop innovative solutions.

Thursday, March 12, is the big day: A research rocket from the REXUS program launched into the stratosphere from the Esrange Space Center in Sweden, carrying the THRIVE module with components of the cell-based StellarHeal wound care material from Würzburg, Hanover, and Dresden. Preparations for the current rocket launch have been underway since last November, and now it's time to keep our fingers crossed that the experiments yield good results.

As of January 1, 2026, the management of the GLP Test Facility at the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM has changed. Prof. Dr. Armin Braun, Head of the Department of Preclinical Pharmacology and Toxicology, has been appointed Head of the GLP Test Facility. He succeeds Prof. Dr. Norbert Krug, Director of Fraunhofer ITEM, who previously held this responsibility. Dr. Sylvia Escher, Head of the Department of Safety Assessment and Toxicology, has been appointed Deputy Head of the GLP Test Facility.

The collaborative project “iGUARD – Inhalable RNA Therapeutics for Targeted Treatment of Lung Diseases” has been honored with the Lower Saxony Innovation Award 2025. The team of researchers from Hannover Medical School (MHH) and the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM received the award in the category “Knowledge and Technology Transfer.” The prize was presented on November 4, 2025, at a formal ceremony in Hannover by Falko Mohrs, Lower Saxony’s Minister for Science and Culture.

The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM has now been officially accredited by AAALAC International (Association for Assessment and Accreditation of Laboratory Animal Care International). This underlines the institute’s commitment to a responsible, ethical, and humane use of animals in research – going beyond legal requirements.

Approximately five million people worldwide suffer from chronic inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. Despite modern therapies, many immunological mechanisms underlying the disease remain poorly understood – posing a key challenge for the development of new targeted treatments.

Fraunhofer ITEM has been officially included in the list of so-called Article 36 organizations – an important step for our role in the European research landscape for food safety.

How many birch pollen particles in the air trigger symptoms in individuals with allergies? A recent study published in the journal International Archives of Allergy and Immunology provides an answer: allergic symptoms occur at concentrations of 50 - 100 pollen per cubic meter of air.

Targeted nerve stimulation instead of drugs: With the kick-off of the PREPARE project DUSTIN, a promising research alliance for the visionary treatment of autoimmune diseases is starting its work. Four Fraunhofer Institutes are pooling their expertise to develop a miniaturized, battery-free implant that communicates and is powered by ultrasound. The project is receiving €3.5 million in funding.

The Pharmaceutical Biotechnology division at the Braunschweig location of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, one of the institute’s five research divisions at three different locations, is to be closed as of February 28, 2026. The research division has been operating at an ongoing deficit, with little likelihood of this changing in the future. The executive board of the Fraunhofer-Gesellschaft has now approved the request to this effect made by the institute management. One possible solution for maintaining the Braunschweig location remains – the transfer to a private company.